A brief history of how one company helped pioneer a novel therapy and a new wave of innovati-Ben Clark-06/25/2013 - 8:30am

Event Information
Event Topic: 
A brief history of how one company helped pioneer a novel therapy and a new wave of innovati
Event Date: 
06/25/2013 - 8:30am
Event Location: 
Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA
Speaker Information
Event Speaker: 
Ben Clark
Event Speaker Title: 
Engineering Manager
Event Speaker Company: 
Event Speaker Bio: 

Ben Clark

Ben Clark is an Engineering Manager at Medtronic's Renal Denervation division. He has been leading catheter development projects for renal denervation since he joined Ardian in 2005. While at Ardian he worked with a startup team to pioneer renal denervation as a treatment for hypertension by developing the Symplicity catheter, developing novel methods for preclinical evaluation, and supporting early clinical trials in Australia and Europe. Prior to joining Ardian, Ben worked as a Research & Development and Manufacturing Engineer for startup companies developing mechanical devices for arterial access site closure (Perclose, acquired by Abbott Laboratories), and crossing chronic total occlusions (LuMend, acquired by Johnson & Johnson). Ben has a BS in Mechanical Engineering from Cal Poly State University in San Luis Obispo and is a licensed professional engineer in the state of California. He currently holds 8 issued US patents.

Event Details
Event Details: 

Renal denervation (RDN) is a novel procedure that has gained significant attention from the medical device community, including researchers across many disciplines, device companies, and entrepreneurs. This presentation will begin by describing the roles of the kidneys and renal nerves within the sympathetic nervous system. Then Ben will share his unique startup experience of developing various technologies before arriving at a customized approach of radiofrequency (RF) ablation to help pioneer a novel therapy and a new wave of scientific and device innovation.